MCID: LNG039
MIFTS: 54

Lung Squamous Cell Carcinoma malady

Categories: Cancer diseases, Respiratory diseases, Skin diseases

Aliases & Classifications for Lung Squamous Cell Carcinoma

Aliases & Descriptions for Lung Squamous Cell Carcinoma:

Name: Lung Squamous Cell Carcinoma 12 14
Squamous Cell Carcinoma of Lung 12 29 69
Epidermoid Cell Carcinoma of the Lung 12
Squamous Cell Lung Cancer 52

Classifications:



External Ids:

Disease Ontology 12 DOID:3907
NCIt 47 C3493
SNOMED-CT 64 254634000
UMLS 69 C0149782

Summaries for Lung Squamous Cell Carcinoma

Disease Ontology : 12 A non-small cell lung carcinoma that has material basis in the squamous cell.

MalaCards based summary : Lung Squamous Cell Carcinoma, also known as squamous cell carcinoma of lung, is related to peritoneal mesothelioma and lung occult squamous cell carcinoma. An important gene associated with Lung Squamous Cell Carcinoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Nanog in Mammalian ESC Pluripotency. The drugs Paclitaxel and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include lung, bone and brain, and related phenotypes are Decreased viability and growth/size/body region

Wikipedia : 71 Squamous-cell carcinoma (SCC) of the lung is a type of non-small-cell lung carcinoma and is more common... more...

Related Diseases for Lung Squamous Cell Carcinoma

Diseases related to Lung Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 92)
id Related Disease Score Top Affiliating Genes
1 peritoneal mesothelioma 29.2 KRAS KRT19 PIK3CA TP53
2 lung occult squamous cell carcinoma 11.0
3 lung mixed small cell and squamous cell carcinoma 11.0
4 squamous cell carcinoma 10.9
5 adenocarcinoma 10.4
6 pkp1-related ectodermal dysplasia/skin fragility syndrome 10.3 FGFR1 FGFR2
7 pitx3-related anterior segment mesenchymal dysgenesis 10.3 FGFR1 FGFR2
8 wolffian adnexal neoplasm 10.3 EGFR TP53
9 acrodermatitis chronica atrophicans 10.3 ALK TP53
10 exudative glomerulonephritis 10.2 EGFR KRAS TP53
11 estrogen-receptor positive breast cancer 10.2 EGFR S100A7 TP53
12 ovarian embryonal carcinoma 10.2 ALK EGFR TP53
13 early myoclonic encephalopathy 10.2 EGFR FGFR1 TP53
14 spastic paraplegia 1 10.2 EGFR PIK3CA TP53
15 brachial plexus neuropathy 10.2 EGFR KRAS TP53
16 reactive arthritis 10.2 EGFR PIK3CA TP53
17 oral leukoedema 10.2 EGFR FGFR1 PTHLH
18 precursor t-lymphoblastic lymphoma/leukemia 10.2 EGFR KRAS PIK3CA
19 childhood-onset cerebral x-linked adrenoleukodystrophy 10.2 EGFR SOX2 TP53
20 adult syndrome 10.2 KRAS PIK3CA TP53
21 gastric cancer, somatic 10.2 FGFR2 KRAS PIK3CA
22 benign ependymoma 10.2 EGFR KRAS PTHLH TP53
23 progesterone-receptor negative breast cancer 10.2 FGFR2 PIK3CA TP53
24 prostatic adenoma 10.1 EGFR KRAS TP53
25 secondary corneal edema 10.1 CYP1A1 KRT19 TP53
26 paroxysmal nocturnal hemoglobinuria 10.1 EGFR KRAS TP53
27 spongiotic dermatitis 10.1 CYP1A1 EGFR KRAS PIK3CA
28 progesterone-receptor positive breast cancer 10.1 EGFR S100A7 TP53
29 allergic contact dermatitis 10.1 ALK EGFR KRAS TP53
30 fallopian tube papillary adenocarcinoma 10.1 ALK KEAP1 NFE2L2 TP53
31 myxedema 10.1 EGFR KRAS PIK3CA TP53
32 papillary adenofibroma 10.1 KRAS KRT19 TP53
33 dental caries 10.1 EGFR KRAS PIK3CA TP53
34 ossifying fibromyxoid tumor 10.1 KRAS KRT19 TP53
35 nasal cavity disease 10.1 EGFR KRAS PIK3CA TP53
36 uterine corpus endometrial stromal sarcoma 10.1 KRAS PIK3CA PTHLH TP53
37 non-distal monosomy 10q 10.1 ALK EGFR KRAS TP53
38 trachea squamous cell carcinoma 10.1 EGFR KRAS PIK3CA TP53
39 metagonimiasis 10.1 FGFR1 KRT19 TP53
40 mediastinum synovial sarcoma 10.1 NAPSA PIK3CA TP53
41 ornithinemia 10.1 CYP1A1 EGFR KRT19 TP53
42 familial porphyria cutanea tarda 10.1 FGFR1 FGFR2
43 oral squamous cell carcinoma 10.1 EGFR KRAS TP53
44 kidney clear cell sarcoma 10.1 ALK EGFR KRAS PIK3CA
45 vascular hemostatic disease 10.1 ALK EGFR KRAS PIK3CA
46 pulmonary fibrosis and/or bone marrow failure, telomere-related, 1 10.1 EGFR KRAS NAPSA TP53
47 basophilic carcinoma 10.0 GPC3 KRAS KRT19 TP53
48 testicular cancer 10.0 EGFR FGFR2 KRAS NAPSA TP53
49 nail disorder, nonsyndromic congenital, 3, 10.0 CYP1A1 EGFR KRAS PIK3CA TP53
50 muscular dystrophy-dystroglycanopathy , type b, 2 9.9 EGFR FGFR2 KRAS PIK3CA TP53

Graphical network of the top 20 diseases related to Lung Squamous Cell Carcinoma:



Diseases related to Lung Squamous Cell Carcinoma

Symptoms & Phenotypes for Lung Squamous Cell Carcinoma

GenomeRNAi Phenotypes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.26 EGFR KRAS PIK3CA
2 Decreased viability GR00106-A-0 10.26 KRAS
3 Decreased viability GR00107-A-1 10.26 PRKCI
4 Decreased viability GR00221-A-1 10.26 KRAS EGFR PIK3CA PRKCI SOX2 ALK
5 Decreased viability GR00221-A-2 10.26 KRAS PIK3CA PRKCI FGFR1
6 Decreased viability GR00221-A-3 10.26 PRKCI
7 Decreased viability GR00221-A-4 10.26 EGFR PIK3CA PRKCI SOX2 ALK
8 Decreased viability GR00301-A 10.26 KRAS
9 Decreased viability GR00381-A-1 10.26 KRAS
10 Decreased cell migration GR00055-A-1 9.55 ALK EGFR KRAS PIK3CA PRKCI
11 Increased cell death HMECs cells GR00103-A-0 9.1 EGFR FGFR1 KEAP1 PIK3CA S100A7 TP53

MGI Mouse Phenotypes related to Lung Squamous Cell Carcinoma:

44 (show all 26)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.46 ALK CYP1A1 EGFR FGFR1 FGFR2 GPC3
2 homeostasis/metabolism MP:0005376 10.41 EGFR FGFR1 FGFR2 GPC3 KEAP1 KRAS
3 cardiovascular system MP:0005385 10.4 TP53 FGFR1 FGFR2 GPC3 KRAS KRT19
4 cellular MP:0005384 10.4 EGFR FGFR1 FGFR2 GPC3 KRAS KRT19
5 mortality/aging MP:0010768 10.39 KRAS KRT19 NFE2L2 PIK3CA PRKCI PTHLH
6 endocrine/exocrine gland MP:0005379 10.37 KRAS KRT19 PIK3CA PRKCI PTHLH SOX2
7 integument MP:0010771 10.36 NFE2L2 PIK3CA PTHLH SOX2 TP53 ALK
8 digestive/alimentary MP:0005381 10.35 EGFR FGFR1 FGFR2 GPC3 KEAP1 KRAS
9 embryo MP:0005380 10.34 EGFR FGFR1 FGFR2 GPC3 KRAS KRT19
10 immune system MP:0005387 10.34 CYP1A1 EGFR FGFR1 FGFR2 GPC3 KRAS
11 craniofacial MP:0005382 10.26 EGFR FGFR1 FGFR2 GPC3 KRAS NFE2L2
12 nervous system MP:0003631 10.23 KRAS KRT19 NFE2L2 PIK3CA PRKCI PTHLH
13 adipose tissue MP:0005375 10.17 EGFR FGFR2 NFE2L2 PIK3CA PRKCI PTHLH
14 neoplasm MP:0002006 10.13 ALK EGFR FGFR2 KRAS KRT19 NFE2L2
15 muscle MP:0005369 10.1 FGFR1 FGFR2 KRAS PIK3CA PRKCI SOX2
16 no phenotypic analysis MP:0003012 10.09 CYP1A1 EGFR FGFR1 FGFR2 KRAS KRT19
17 limbs/digits/tail MP:0005371 10.08 EGFR FGFR1 FGFR2 GPC3 KRAS PTHLH
18 liver/biliary system MP:0005370 10.07 CYP1A1 EGFR FGFR2 KRAS NFE2L2 PRKCI
19 normal MP:0002873 10.06 CYP1A1 EGFR FGFR1 FGFR2 KRAS KRT19
20 hearing/vestibular/ear MP:0005377 10.05 TP53 EGFR FGFR1 FGFR2 KRAS SOX2
21 reproductive system MP:0005389 10 ALK EGFR FGFR1 FGFR2 GPC3 KRAS
22 pigmentation MP:0001186 9.97 ALK EGFR FGFR2 GPC3 KRAS PRKCI
23 renal/urinary system MP:0005367 9.97 EGFR FGFR1 FGFR2 GPC3 KRAS NFE2L2
24 respiratory system MP:0005388 9.85 ALK EGFR FGFR2 GPC3 KEAP1 KRAS
25 skeleton MP:0005390 9.73 KRAS KRT19 NFE2L2 PIK3CA PTHLH SOX2
26 vision/eye MP:0005391 9.32 ALK EGFR FGFR1 FGFR2 KRAS PIK3CA

Drugs & Therapeutics for Lung Squamous Cell Carcinoma

Drugs for Lung Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 282)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 33069-62-4 36314
2
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 15663-27-1 84093 441203 2767
3
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 41575-94-4 10339178 498142 38904
4
Gemcitabine Approved Phase 4,Phase 3,Phase 2,Phase 1 95058-81-4 60750
5
Gefitinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 184475-35-2 123631
6
Pemetrexed Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 150399-23-8, 137281-23-3 446556 60843
7
Nedaplatin Approved Phase 4,Phase 3,Phase 2 95734-82-0
8
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 216974-75-3
9
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-05-9 54575, 6560146 143
10
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 59-30-3 6037
11
Docetaxel Approved May 1996, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 114977-28-5 148124 9877265
12
Erlotinib Hydrochloride Phase 4,Phase 3,Phase 2,Phase 1 183319-69-9 176871
13 Endostatins Phase 4,Phase 3,Phase 1,Phase 2 71581480
14 Folic Acid Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
15 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
16 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
17 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
18 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 2,Phase 1
19 Vitamin B Complex Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
20 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
23 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
24 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
25 Antimitotic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
27 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
28 Folate Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
29 Cola Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
30 Vitamin B9 Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
31 tyrosine Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1
32
Etoposide Approved Phase 3,Phase 1,Phase 2 33419-42-0 36462
33
Vinorelbine Approved, Investigational Phase 3,Phase 2,Phase 1 71486-22-1 60780 44424639
34
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
35
Cetuximab Approved Phase 3,Phase 1,Phase 2 205923-56-4 56842117 2333
36
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
37
Vinblastine Approved Phase 3,Phase 2,Phase 1 865-21-4 13342 241903
38
Celecoxib Approved, Investigational Phase 3,Phase 2 169590-42-5 2662
39
Sorafenib Approved, Investigational Phase 3,Phase 1,Phase 2 284461-73-0 216239 406563
40
Capecitabine Approved, Investigational Phase 2, Phase 3,Phase 1 154361-50-9 60953
41
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
42
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
43
Vindesine Approved Phase 3 59917-39-4, 53643-48-4 40839
44
Succinylcholine Approved Phase 3,Phase 2,Phase 1 306-40-1 5314
45
Crizotinib Approved Phase 3,Phase 2,Phase 1 877399-52-5 11626560 10366136 10366137 10366138 10366139 10366140 10366141
46
Pembrolizumab Approved Phase 3,Phase 1,Phase 2 1374853-91-4
47
Palbociclib Approved Phase 2, Phase 3, Phase 1 571190-30-2 11431660 5005498 5330286
48
nivolumab Approved Phase 3,Phase 2,Phase 1 946414-94-4
49
Adenosine Approved, Investigational Phase 3 58-61-7 60961
50
Cytarabine Approved, Investigational Phase 3 147-94-4 6253

Interventional clinical trials:

(show top 50) (show all 517)
id Name Status NCT ID Phase
1 Nedaplatin (Jiebaishu®) Combined With Docetaxel for Advanced Lung Squamous Cell Carcinoma Completed NCT02088515 Phase 4
2 Post-marketing Surveillance Study of Docetaxel-Based Chemotherapy Completed NCT02972216 Phase 4
3 A Study of Avastin in Combination With Chemotherapy for Treatment of Colorectal Cancer and Non-Small Cell Lung Cancer (ARIES) Completed NCT00388206 Phase 4
4 Endostar First-line Treatment of Advanced Non-small Cell Lung Squamous Carcinoma Recruiting NCT02513342 Phase 4
5 Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer Recruiting NCT02031601 Phase 4
6 An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck Active, not recruiting NCT00684385 Phase 4
7 Safety and Efficacy Study of Abraxane in Combination With Carboplatin to Treat Advanced NSCL Cancer in the Elderly Active, not recruiting NCT02151149 Phase 4
8 Lipusu Advanced Squamous Cell Carcinoma of Lung Study Carboplatin in Advanced Squamous Cell Carcinoma of Lung Not yet recruiting NCT02996214 Phase 4
9 Metronomic Cyclophosphamide in Combination With Standard Chemotherapy for Squamous Cell Lung Carcinoma Unknown status NCT01947062 Phase 3
10 Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer Unknown status NCT00955695 Phase 3
11 Efficacy of Optically-guided Surgery in the Management of Early-staged Oral Cancer - COOLS TRIAL Unknown status NCT01039298 Phase 3
12 Chemoradiation With or Without Nimotuzumab in Treating Esophageal Cancer Patients Who Suffer With Recurrence in Regional Lymph Nodes After Esophagectomy Unknown status NCT01402180 Phase 2, Phase 3
13 Trial of Gemcitabine/Carboplatin With or Without Iniparib (SAR240550) (a PARP1 Inhibitor) in Subjects With Previously Untreated Stage IV Squamous Non-Small-Cell Lung Cancer (NSCLC) Completed NCT01082549 Phase 3
14 Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®. Completed NCT01652469 Phase 3
15 Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery Completed NCT00003387 Phase 3
16 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
17 Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Completed NCT00002852 Phase 3
18 Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer Completed NCT00002550 Phase 3
19 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed Completed NCT00003235 Phase 3
20 Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00005838 Phase 3
21 Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Completed NCT00020709 Phase 3
22 Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Completed NCT00049543 Phase 3
23 Chemotherapy Followed by Surgery or Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer Completed NCT00002623 Phase 3
24 Chemotherapy and Radiation Therapy With or Without Epoetin Alfa in Treating Patients With Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer Completed NCT00028938 Phase 3
25 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
26 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3
27 Vinorelbine, Gemcitabine, and Docetaxel Compared With Paclitaxel and Carboplatin in Treating Patients With Advanced Non-Small Cell Lung Cancer Completed NCT00079287 Phase 3
28 Paclitaxel With or Without Carboplatin in Treating Patients With Advanced Non-small Cell Lung Cancer Completed NCT00003117 Phase 3
29 Radiation Therapy to Relieve Symptoms in Patients With Non-small Cell Lung Cancer Completed NCT00003685 Phase 3
30 Combination Chemotherapy Compared With No Treatment Following Surgery in Treating Patients With Non-small Cell Lung Cancer Completed NCT00002823 Phase 3
31 TAilored Post-Surgical Therapy in Early Stage NSCLC Completed NCT00775385 Phase 2, Phase 3
32 ZD6474 (ZACTIMA™) Phase III Study in EGFR Failures Completed NCT00404924 Phase 3
33 An Analysis of the Response of Human Tumor Microvascular Endothelium to Ionizing Radiation Completed NCT00132704 Phase 3
34 Chemotherapy and Radiation in Treating Participants With Stage 3 Non-Small Cell Lung Cancer Completed NCT00686959 Phase 3
35 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
36 A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Ce Completed NCT00449033 Phase 3
37 S1400I Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Recruiting NCT02785952 Phase 3
38 S1400 Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer Recruiting NCT02154490 Phase 2, Phase 3
39 Nedaplatin/Docetaxel Versus Cisplatin/Docetaxel in Treatment of Advanced/Relapsed Squamous Cell Lung Cancer Recruiting NCT02643407 Phase 3
40 To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer Recruiting NCT02974426 Phase 3
41 Microwave Plus Chemotherapy Versus Chemotherapy for Advanced NSCLC Recruiting NCT02455843 Phase 3
42 Safety and Efficacy Study of Abraxane as Maintenance Treatment After Abraxane Plus Carboplatin in 1st Line Stage IIIB / IV Squamous Cell Non-small Cell Lung Cancer Recruiting NCT02027428 Phase 3
43 Pemetrexed in Advanced Non-Small-Cell Lung Cancer: at Progression vs Maintenance Therapy After Induction Chemotherapy Recruiting NCT02004184 Phase 3
44 The Optimal Intervention Time of Radiotherapy for Oligometastatic Stage IV Non-small Cell Lung Cancer(NSCLC) Recruiting NCT02076477 Phase 3
45 Early Palliative Care in Metastatic Esophageal Squamous Carcinoma (ESCC) and Gastric Cancer Recruiting NCT02375997 Phase 3
46 ALTA-1L Study: A Phase 3 Study of Brigatinib Versus Crizotinib in ALK-positive Advanced Non-Small Cell Lung Cancer Patients Recruiting NCT02737501 Phase 3
47 Study of Chemoradiotherapy in Oesophageal Cancer Including PET Response and Dose Escalation Recruiting NCT02741856 Phase 2, Phase 3
48 Is ENI Necessary For Patients With Thoracic Esophageal Cancer After Esophagectomy And With Pathological Stage Of T1-2,N+,M0 Recruiting NCT01398449 Phase 3
49 A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] Recruiting NCT02409342 Phase 3
50 A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-paclitaxel Compared With Carboplatin + Nab-paclitaxel in Participants With Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) [IMpower 131] Recruiting NCT02367794 Phase 3

Search NIH Clinical Center for Lung Squamous Cell Carcinoma

Genetic Tests for Lung Squamous Cell Carcinoma

Genetic tests related to Lung Squamous Cell Carcinoma:

id Genetic test Affiliating Genes
1 Squamous Cell Carcinoma of Lung 29

Anatomical Context for Lung Squamous Cell Carcinoma

MalaCards organs/tissues related to Lung Squamous Cell Carcinoma:

39
Lung, Bone, Brain, Lymph Node, T Cells, Endothelial, B Cells

Publications for Lung Squamous Cell Carcinoma

Articles related to Lung Squamous Cell Carcinoma:

(show top 50) (show all 266)
id Title Authors Year
1
Identification of long noncoding RNAs for the detection of early stage lung squamous cell carcinoma by microarray analysis. ( 28076325 )
2017
2
Sex-Determining Region Y-box 2 Promotes Growth of Lung Squamous Cell Carcinoma and Directly Targets Cyclin D1. ( 28151013 )
2017
3
Co-expression network analysis of long noncoding RNAs (IncRNAs) and cancer genes revealsSFTA1P and CASC2abnormalities in lung squamous cell carcinoma. ( 28118064 )
2017
4
Claudin-5, -7, and -18 suppress proliferation mediated by inhibition of phosphorylation of Akt in human lung squamous cell carcinoma. ( 27884700 )
2017
5
STXBP4 drives tumor growth and is associated with poor prognosis through PDGF Receptor signaling in lung squamous cell carcinoma. ( 28087642 )
2017
6
Identification of Key Transcription Factors Associated with Lung Squamous Cell Carcinoma. ( 28081052 )
2017
7
Epigenetic upregulation of ARL4C, due to DNA hypomethylation in the 3'-untranslated region, promotes tumorigenesis of lung squamous cell carcinoma. ( 27835592 )
2016
8
Whole exome sequencing of independent lung adenocarcinoma, lung squamous cell carcinoma, and malignant peritoneal mesothelioma: A case report. ( 27902597 )
2016
9
Multiple mutations of lung squamous cell carcinoma shared common mechanisms. ( 27835590 )
2016
10
Identification of FGF19 as a prognostic marker and potential driver gene of lung squamous cell carcinomas in Chinese smoking patients. ( 26943773 )
2016
11
A Case of Lung Squamous Cell Carcinoma With Duodenal Metastasis on FDG PET/CT. ( 27055139 )
2016
12
Inferring RBP-Mediated Regulation in Lung Squamous Cell Carcinoma. ( 27186987 )
2016
13
SOX2-Induced Lineage Restriction Drives Lung Squamous Cell Carcinoma. ( 27770006 )
2016
14
MicroRNA-588 suppresses tumor cell migration and invasion by targeting GRN in lung squamous cell carcinoma. ( 27571908 )
2016
15
Targeted depletion of PIK3R2 induces regression of lung squamous cell carcinoma. ( 27835880 )
2016
16
Regulation of TPD52 by antitumor microRNA-218 suppresses cancer cell migration and invasion in lung squamous cell carcinoma. ( 27633630 )
2016
17
Downregulation of selenium-binding protein 1 is associated with poor prognosis in lung squamous cell carcinoma. ( 26956891 )
2016
18
Molecular Mechanism of Cinnamomum verum Component Cuminaldehyde Inhibits Cell Growth and Induces Cell Death in Human Lung Squamous Cell Carcinoma NCI-H520 Cells In Vitro and In Vivo. ( 26918037 )
2016
19
72P Differential expression profile of lung squamous cell carcinoma (LSCC) cell lines as a mean to predict drug interaction effects. ( 27198427 )
2016
20
Plasma miR-324-3p and miR-1285 as diagnostic and prognostic biomarkers for early stage lung squamous cell carcinoma. ( 27517633 )
2016
21
Programmed cell death-ligand 1 (PD-L1) expression and fibroblast growth factor receptor 1 (FGFR1) amplification in stage III/IV lung squamous cell carcinoma (SQC). ( 28008744 )
2016
22
Identification of differentially expressed genes between lung adenocarcinoma and lung squamous cell carcinoma by gene expression profiling. ( 27356570 )
2016
23
SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma. ( 26846300 )
2016
24
FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. ( 27581340 )
2016
25
Lung squamous cell carcinoma with brachial soft tissue metastasis responsive to gefitinib: Report of a rare case. ( 27755795 )
2016
26
ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. ( 26973202 )
2016
27
Q787Q EGFR Polymorphism as a Prognostic Factor for Lung Squamous Cell Carcinoma. ( 26999786 )
2016
28
Mutations and expression of the NFE2L2/KEAP1/CUL3 pathway in Chinese patients with lung squamous cell carcinoma. ( 27499952 )
2016
29
Elevated eukaryotic elongation factor 2 expression is involved in proliferation and invasion of lung squamous cell carcinoma. ( 27542262 )
2016
30
Differential diagnosis between primary lung squamous cell carcinoma and pulmonary metastasis of head and neck squamous cell carcinoma. ( 26813704 )
2016
31
Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the treatment of lung squamous cell carcinoma. ( 26684028 )
2016
32
MicroRNAs modulate the expression of the SOX18 transcript in lung squamous cell carcinoma. ( 27666488 )
2016
33
Incidence of Brain Metastasis at the Initial Diagnosis of Lung Squamous Cell Carcinoma on the Basis of Stage, Excluding Brain Metastasis. ( 26746367 )
2016
34
Identification of a seven-miRNA signature as prognostic biomarker for lung squamous cell carcinoma. ( 27835574 )
2016
35
Deguelin Induces the Apoptosis of Lung Squamous Cell Carcinoma Cells through Regulating the Expression of Galectin-1. ( 27313498 )
2016
36
WIF-1 and Ihh Expression and Clinical Significance in Patients With Lung Squamous Cell Carcinoma and Adenocarcinoma. ( 27801732 )
2016
37
Co-localization of Ki67, CD44v adn deltaNp63 in the invasive front of lung squamous cell carcinoma. ( 26919615 )
2016
38
Altered expression of programmed death-ligand 1 after neo-adjuvant chemotherapy in patients with lung squamous cell carcinoma. ( 27565935 )
2016
39
Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. ( 27663899 )
2016
40
GATA3 immunohistochemical stain is a highly sensitive tool for distinguishing between upper urothelial tract urothelial carcinoma and lung squamous cell carcinoma and adenocarcinoma. ( 27773096 )
2016
41
Identification of crucial regulatory relationships between long non-coding RNAs and protein-coding genes in lung squamous cell carcinoma. ( 26928440 )
2016
42
Inhibition of Glutaminolysis Inhibits Cell Growth via Down-regulating Mtorc1 Signaling in Lung Squamous Cell Carcinoma. ( 27793929 )
2016
43
SOX2 and PI3K Cooperate to Induce and Stabilize a Squamous-Committed Stem Cell Injury State during Lung Squamous Cell Carcinoma Pathogenesis. ( 27880766 )
2016
44
Distinguishing Lung Adenocarcinoma from Lung Squamous Cell Carcinoma by Two Hypomethylated and Three Hypermethylated Genes: A Meta-Analysis. ( 26862903 )
2016
45
Cinnamomum verum ingredient 2-methoxycinnamaldehyde: a new antiproliferative drug targeting topoisomerase I and II in human lung squamous cell carcinoma NCI-H520 cells. ( 27192048 )
2016
46
A Two-gene Prognostic Classifier for Early Stage Lung Squamous Cell Carcinoma in multiple large-scale and geographically diverse cohorts. ( 27613525 )
2016
47
LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma. ( 27903974 )
2016
48
Phospholipid profiling identifies acyl chain elongation as a ubiquitous trait and potential target for the treatment of lung squamous cell carcinoma. ( 26862848 )
2016
49
Bronchial airway gene expression signatures in mouse lung squamous cell carcinoma and their modulation by cancer chemopreventive agents. ( 27935865 )
2016
50
Retraction Note: Psoriasin (S100A7) is a novel biomarker for lung squamous cell carcinoma in humans. ( 27252596 )
2016

Variations for Lung Squamous Cell Carcinoma

ClinVar genetic disease variations for Lung Squamous Cell Carcinoma:

6 (show top 50) (show all 57)
id Gene Variation Type Significance SNP ID Assembly Location
1 PTEN NM_000314.6(PTEN): c.389G> A (p.Arg130Gln) single nucleotide variant Pathogenic/Likely pathogenic rs121909229 GRCh37 Chromosome 10, 89692905: 89692905
2 TP53 NM_000546.5(TP53): c.742C> T (p.Arg248Trp) single nucleotide variant Pathogenic/Likely pathogenic rs121912651 GRCh37 Chromosome 17, 7577539: 7577539
3 TP53 NM_000546.5(TP53): c.733G> T (p.Gly245Cys) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
4 TP53 NM_000546.5(TP53): c.725G> A (p.Cys242Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121912655 GRCh37 Chromosome 17, 7577556: 7577556
5 TP53 NM_000546.5(TP53): c.734G> A (p.Gly245Asp) single nucleotide variant Pathogenic/Likely pathogenic rs121912656 GRCh37 Chromosome 17, 7577547: 7577547
6 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
7 TP53 NM_000546.5(TP53): c.733G> A (p.Gly245Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934575 GRCh37 Chromosome 17, 7577548: 7577548
8 TP53 NM_000546.5(TP53): c.818G> A (p.Arg273His) single nucleotide variant Pathogenic/Likely pathogenic rs28934576 GRCh37 Chromosome 17, 7577120: 7577120
9 TP53 NM_000546.5(TP53): c.451C> A (p.Pro151Thr) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
10 TP53 NM_000546.5(TP53): c.451C> T (p.Pro151Ser) single nucleotide variant Pathogenic/Likely pathogenic rs28934874 GRCh37 Chromosome 17, 7578479: 7578479
11 TP53 NM_000546.5(TP53): c.659A> C (p.Tyr220Ser) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
12 KRAS NM_033360.3(KRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913530 GRCh37 Chromosome 12, 25398285: 25398285
13 HRAS NM_005343.3(HRAS): c.37G> T (p.Gly13Cys) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
14 FGFR2 NM_000141.4(FGFR2): c.870G> C (p.Trp290Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121918499 GRCh37 Chromosome 10, 123279562: 123279562
15 PTPN11 NM_002834.4(PTPN11): c.226G> A (p.Glu76Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121918464 GRCh37 Chromosome 12, 112888210: 112888210
16 PTPN11 NM_002834.4(PTPN11): c.227A> G (p.Glu76Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
17 PTPN11 NM_002834.4(PTPN11): c.227A> C (p.Glu76Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121918465 GRCh37 Chromosome 12, 112888211: 112888211
18 PIK3CA NM_006218.3(PIK3CA): c.3140A> G (p.His1047Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
19 PIK3CA NM_006218.3(PIK3CA): c.3140A> T (p.His1047Leu) single nucleotide variant Pathogenic/Likely pathogenic rs121913279 GRCh37 Chromosome 3, 178952085: 178952085
20 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
21 PIK3CA NM_006218.3(PIK3CA): c.1634A> G (p.Glu545Gly) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
22 PIK3CA NM_006218.3(PIK3CA): c.1634A> C (p.Glu545Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913274 GRCh37 Chromosome 3, 178936092: 178936092
23 BRAF NM_004333.4(BRAF): c.1397G> T (p.Gly466Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913351 GRCh37 Chromosome 7, 140481411: 140481411
24 BRAF NM_004333.4(BRAF): c.1405G> C (p.Gly469Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913357 GRCh37 Chromosome 7, 140481403: 140481403
25 BRAF NM_004333.4(BRAF): c.1406G> C (p.Gly469Ala) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
26 BRAF NM_004333.4(BRAF): c.1406G> A (p.Gly469Glu) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
27 AKT1 NM_005163.2(AKT1): c.49G> A (p.Glu17Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121434592 GRCh37 Chromosome 14, 105246551: 105246551
28 FGFR3 NM_000142.4(FGFR3): c.742C> T (p.Arg248Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913482 GRCh37 Chromosome 4, 1803564: 1803564
29 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
30 PIK3CA NM_006218.3(PIK3CA): c.1624G> A (p.Glu542Lys) single nucleotide variant Pathogenic/Likely pathogenic rs121913273 GRCh37 Chromosome 3, 178936082: 178936082
31 PIK3CA NM_006218.3(PIK3CA): c.1258T> C (p.Cys420Arg) single nucleotide variant Pathogenic/Likely pathogenic rs121913272 GRCh37 Chromosome 3, 178927980: 178927980
32 HRAS NM_005343.3(HRAS): c.37G> C (p.Gly13Arg) single nucleotide variant Pathogenic/Likely pathogenic rs104894228 GRCh37 Chromosome 11, 534286: 534286
33 PIK3CA NM_006218.3(PIK3CA): c.3139C> T (p.His1047Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs121913281 GRCh37 Chromosome 3, 178952084: 178952084
34 BRAF NM_004333.4(BRAF): c.1406G> T (p.Gly469Val) single nucleotide variant Pathogenic/Likely pathogenic rs121913355 GRCh37 Chromosome 7, 140481402: 140481402
35 KRAS NM_033360.3(KRAS): c.183A> T (p.Gln61His) single nucleotide variant Pathogenic/Likely pathogenic rs17851045 GRCh37 Chromosome 12, 25380275: 25380275
36 EGFR NM_005228.4(EGFR): c.2303G> T (p.Ser768Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913465 GRCh37 Chromosome 7, 55249005: 55249005
37 TP53 NM_000546.5(TP53): c.488A> G (p.Tyr163Cys) single nucleotide variant Pathogenic/Likely pathogenic rs148924904 GRCh37 Chromosome 17, 7578442: 7578442
38 TP53 NM_000546.5(TP53): c.535C> T (p.His179Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587780070 GRCh37 Chromosome 17, 7578395: 7578395
39 TP53 NM_000546.5(TP53): c.659A> G (p.Tyr220Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121912666 GRCh37 Chromosome 17, 7578190: 7578190
40 TP53 NM_000546.5(TP53): c.701A> G (p.Tyr234Cys) single nucleotide variant Pathogenic/Likely pathogenic rs587780073 GRCh37 Chromosome 17, 7577580: 7577580
41 TP53 NM_000546.5(TP53): c.638G> A (p.Arg213Gln) single nucleotide variant Pathogenic/Likely pathogenic rs587778720 GRCh38 Chromosome 17, 7674893: 7674893
42 TP53 NM_000546.5(TP53): c.422G> A (p.Cys141Tyr) single nucleotide variant Pathogenic/Likely pathogenic rs587781288 GRCh37 Chromosome 17, 7578508: 7578508
43 TP53 NM_000546.5(TP53): c.844C> G (p.Arg282Gly) single nucleotide variant Pathogenic/Likely pathogenic rs28934574 GRCh37 Chromosome 17, 7577094: 7577094
44 TP53 NM_000546.5(TP53): c.842A> G (p.Asp281Gly) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh37 Chromosome 17, 7577096: 7577096
45 TP53 NM_000546.5(TP53): c.706T> G (p.Tyr236Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587782289 GRCh37 Chromosome 17, 7577575: 7577575
46 PIK3CA NM_006218.3(PIK3CA): c.353G> A (p.Gly118Asp) single nucleotide variant Pathogenic/Likely pathogenic rs587777790 GRCh38 Chromosome 3, 179199690: 179199690
47 EGFR NM_005228.4(EGFR): c.2582T> A (p.Leu861Gln) single nucleotide variant Pathogenic/Likely pathogenic,drug response rs121913444 GRCh37 Chromosome 7, 55259524: 55259524
48 HRAS NM_005343.3(HRAS): c.38G> T (p.Gly13Val) single nucleotide variant Pathogenic/Likely pathogenic rs104894226 GRCh38 Chromosome 11, 534285: 534285
49 TP53 NM_000546.5(TP53): c.842A> T (p.Asp281Val) single nucleotide variant Pathogenic/Likely pathogenic rs587781525 GRCh38 Chromosome 17, 7673778: 7673778
50 TP53 NM_000546.5(TP53): c.584T> C (p.Ile195Thr) single nucleotide variant Pathogenic/Likely pathogenic rs760043106 GRCh38 Chromosome 17, 7674947: 7674947

Cosmic variations for Lung Squamous Cell Carcinoma:

9 (show top 50) (show all 976)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM96301 ZRANB3 lung,NS,carcinoma,squamous cell carcinoma c.1566G>C p.V522V 17
2 COSM95568 ZNF598 lung,NS,carcinoma,squamous cell carcinoma c.551G>A p.R184H 17
3 COSM96300 ZNF331 lung,NS,carcinoma,squamous cell carcinoma c.108G>T p.L36L 17
4 COSM95561 ZMYM2 lung,NS,carcinoma,squamous cell carcinoma c.1484G>T p.C495F 17
5 COSM95691 ZCCHC2 lung,NS,carcinoma,squamous cell carcinoma c.3073G>T p.G1025* 17
6 COSM95554 ZAP70 lung,NS,carcinoma,squamous cell carcinoma c.188G>A p.R63H 17
7 COSM95552 YWHAG lung,NS,carcinoma,squamous cell carcinoma c.113C>T p.S38L 17
8 COSM96294 YWHAE lung,NS,carcinoma,squamous cell carcinoma c.660C>T p.I220I 17
9 COSM95549 YAP1 lung,NS,carcinoma,squamous cell carcinoma c.485A>G p.Q162R 17
10 COSM95539 WWP2 lung,NS,carcinoma,squamous cell carcinoma c.1892A>T p.Y631F 17
11 COSM95536 WT1 lung,NS,carcinoma,squamous cell carcinoma c.857A>G p.Y286C 17
12 COSM95535 WRN lung,NS,carcinoma,squamous cell carcinoma c.3934G>T p.V1312F 17
13 COSM95533 WNT9B lung,NS,carcinoma,squamous cell carcinoma c.109C>A p.P37T 17
14 COSM95530 WNT7B lung,NS,carcinoma,squamous cell carcinoma c.128G>T p.G43V 17
15 COSM95525 WNT2 lung,NS,carcinoma,squamous cell carcinoma c.805G>T p.V269L 17
16 COSM95524 WNT16 lung,NS,carcinoma,squamous cell carcinoma c.217G>T p.G73C 17
17 COSM96286 WNT10B lung,NS,carcinoma,squamous cell carcinoma c.702G>T p.V234V 17
18 COSM95522 WNT10B lung,NS,carcinoma,squamous cell carcinoma c.364T>A p.S122T 17
19 COSM21240 WNK3 lung,NS,carcinoma,squamous cell carcinoma c.2561C>G p.S854C 17
20 COSM96285 WNK1 lung,NS,carcinoma,squamous cell carcinoma c.2094C>T p.V698V 17
21 COSM95502 USP9X lung,NS,carcinoma,squamous cell carcinoma c.6338T>C p.I2113T 17
22 COSM95500 USP9X lung,NS,carcinoma,squamous cell carcinoma c.184G>A p.D62N 17
23 COSM95688 USP9X lung,NS,carcinoma,squamous cell carcinoma c.2794G>T p.E932* 17
24 COSM95493 USP54 lung,NS,carcinoma,squamous cell carcinoma c.1490G>T p.R497L 17
25 COSM95489 USP51 lung,NS,carcinoma,squamous cell carcinoma c.724C>T p.H242Y 17
26 COSM95478 USP40 lung,NS,carcinoma,squamous cell carcinoma c.1034A>T p.K345I 17
27 COSM95468 USP35 lung,NS,carcinoma,squamous cell carcinoma c.400C>T p.H134Y 17
28 COSM96266 USP34 lung,NS,carcinoma,squamous cell carcinoma c.2394A>T p.G798G 17
29 COSM95463 USP34 lung,NS,carcinoma,squamous cell carcinoma c.7832T>C p.M2611T 17
30 COSM95451 USP3 lung,NS,carcinoma,squamous cell carcinoma c.1003G>A p.D335N 17
31 COSM95446 USP28 lung,NS,carcinoma,squamous cell carcinoma c.1342G>T p.V448F 17
32 COSM95445 USP28 lung,NS,carcinoma,squamous cell carcinoma c.2483T>A p.V828D 17
33 COSM95432 USP15 lung,NS,carcinoma,squamous cell carcinoma c.1145A>G p.D382G 17
34 COSM95683 USP12 lung,NS,carcinoma,squamous cell carcinoma c.280C>T p.Q94* 17
35 COSM96311 UBR5 lung,NS,carcinoma,squamous cell carcinoma c.2283G>T p.K761N 17
36 COSM95594 UBR5 lung,NS,carcinoma,squamous cell carcinoma c.5012C>G p.S1671* 17
37 COSM96310 UBR5 lung,NS,carcinoma,squamous cell carcinoma c.3773T>C p.L1258P 17
38 COSM94153 UBR5 lung,NS,carcinoma,squamous cell carcinoma c.6413G>T p.G2138V 17
39 COSM94160 UBR5 lung,NS,carcinoma,squamous cell carcinoma c.491G>A p.G164E 17
40 COSM96259 UBE3C lung,NS,carcinoma,squamous cell carcinoma c.894G>C p.L298L 17
41 COSM95681 UBE3B lung,NS,carcinoma,squamous cell carcinoma c.592G>T p.G198* 17
42 COSM96255 UBE2B lung,NS,carcinoma,squamous cell carcinoma c.306A>G p.V102V 17
43 COSM95417 TTK lung,NS,carcinoma,squamous cell carcinoma c.1420G>A p.D474N 17
44 COSM95411 TRIP12 lung,NS,carcinoma,squamous cell carcinoma c.5368C>G p.L1790V 17
45 COSM95410 TRIP11 lung,NS,carcinoma,squamous cell carcinoma c.5909G>A p.G1970E 17
46 COSM95406 TRIM37 lung,NS,carcinoma,squamous cell carcinoma c.107G>T p.C36F 17
47 COSM95402 TRIM28 lung,NS,carcinoma,squamous cell carcinoma c.1846G>A p.G616S 17
48 COSM12998 TRIM24 lung,NS,carcinoma,squamous cell carcinoma c.1208C>A p.T403N 17
49 COSM95395 TRHR lung,NS,carcinoma,squamous cell carcinoma c.815T>C p.V272A 17
50 COSM95389 TRAF4 lung,NS,carcinoma,squamous cell carcinoma c.1103G>C p.R368P 17

Copy number variations for Lung Squamous Cell Carcinoma from CNVD:

7 (show top 50) (show all 61)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 13957 1 101664084 102994090 Loss COL11A1 Lung squamous cell carcinoma
2 18603 1 146800000 147200000 Loss LOC645166 Lung squamous cell carcinoma
3 18604 1 146800000 147200000 Loss NBPF15 Lung squamous cell carcinoma
4 18605 1 146800000 147200000 Loss NBPF16 Lung squamous cell carcinoma
5 18606 1 146800000 147200000 Loss PPIAL4E Lung squamous cell carcinoma
6 47066 10 89540134 89615643 Loss PTEN Lung squamous cell carcinoma
7 51887 11 132926079 134452384 Loss ACAD8 Lung squamous cell carcinoma
8 58625 11 68821296 70110392 Gain CCND1 Lung squamous cell carcinoma
9 58626 11 68821296 70110392 Gain PPFIA1 Lung squamous cell carcinoma
10 79487 13 72396304 72490843 Loss Lung squamous cell carcinoma
11 89148 15 100100000 100300000 Loss OR4F15 Lung squamous cell carcinoma
12 89149 15 100100000 100300000 Loss OR4F4 Lung squamous cell carcinoma
13 89150 15 100100000 100300000 Loss OR4F6 Lung squamous cell carcinoma
14 105616 16 80626349 81449546 Loss Lung squamous cell carcinoma
15 107157 17 12394069 12459756 Loss Lung squamous cell carcinoma
16 118123 17 7571720 7590868 Mutation TP53 Lung squamous cell carcinoma
17 122933 18 64017241 75522477 Loss CD226 Lung squamous cell carcinoma
18 122934 18 64017241 75522477 Loss MBP Lung squamous cell carcinoma
19 122935 18 64017241 75522477 Loss RTTN Lung squamous cell carcinoma
20 122936 18 64017241 75522477 Loss SOCS6 Lung squamous cell carcinoma
21 128995 19 43840068 44336812 Gain AKT2 Lung squamous cell carcinoma
22 128996 19 43840068 44336812 Gain ECH1 Lung squamous cell carcinoma
23 130187 19 47900000 48300000 Loss PSG1 Lung squamous cell carcinoma
24 130188 19 47900000 48300000 Loss PSG11 Lung squamous cell carcinoma
25 130189 19 47900000 48300000 Loss PSG2 Lung squamous cell carcinoma
26 130190 19 47900000 48300000 Loss PSG3 Lung squamous cell carcinoma
27 130191 19 47900000 48300000 Loss PSG6 Lung squamous cell carcinoma
28 130192 19 47900000 48300000 Loss PSG7 Lung squamous cell carcinoma
29 130193 19 47900000 48300000 Loss PSG8 Lung squamous cell carcinoma
30 131640 19 55600000 55700000 Gain ASPDH Lung squamous cell carcinoma
31 131641 19 55600000 55700000 Gain C19orf63 Lung squamous cell carcinoma
32 131642 19 55600000 55700000 Gain FAM71E1 Lung squamous cell carcinoma
33 131643 19 55600000 55700000 Gain JOSD2 Lung squamous cell carcinoma
34 131644 19 55600000 55700000 Gain MYBPC2 Lung squamous cell carcinoma
35 131645 19 55600000 55700000 Gain NAPSA Lung squamous cell carcinoma
36 131646 19 55600000 55700000 Gain NR1H2 Lung squamous cell carcinoma
37 131647 19 55600000 55700000 Gain POLD1 Lung squamous cell carcinoma
38 131648 19 55600000 55700000 Gain SPIB Lung squamous cell carcinoma
39 149556 11 35116992 35210525 Loss IN Lung squamous cell carcinoma
40 149667 2 91000000 91500000 Loss GGT8P Lung squamous cell carcinoma
41 149668 2 91000000 91500000 Loss LOC654342 Lung squamous cell carcinoma
42 172539 3 183473858 183941579 Gain SOX2 Lung squamous cell carcinoma
43 172540 3 183473858 183941579 Gain TP73L Lung squamous cell carcinoma
44 179006 3 84414538 85858393 Loss POU1F1 Lung squamous cell carcinoma
45 181932 4 130278523 134426567 Loss PLK4 Lung squamous cell carcinoma
46 185649 4 20391110 20848036 Loss BST1 Lung squamous cell carcinoma
47 185650 4 20391110 20848036 Loss PI4K2B Lung squamous cell carcinoma
48 185651 4 20391110 20848036 Loss SLIT2 Lung squamous cell carcinoma
49 191445 5 1 1510601 Gain TERT Lung squamous cell carcinoma
50 202010 5 76066702 76539988 Loss HTR1A Lung squamous cell carcinoma

Expression for Lung Squamous Cell Carcinoma

Search GEO for disease gene expression data for Lung Squamous Cell Carcinoma.

Pathways for Lung Squamous Cell Carcinoma

Pathways related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 46)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.35 EGFR FGFR1 FGFR2 KRAS PIK3CA SOX2
2
Show member pathways
13.23 ALK CDH10 EGFR FGFR1 FGFR2 KRAS
3
Show member pathways
13.05 EGFR FGFR1 FGFR2 KRAS PRKCI TP53
4
Show member pathways
13.03 ALK EGFR FGFR1 FGFR2 KRAS PRKCI
5
Show member pathways
12.84 EGFR FGFR1 FGFR2 KRAS PIK3CA PRKCI
6
Show member pathways
12.83 ALK EGFR FGFR1 FGFR2 KRAS PIK3CA
7 12.69 EGFR FGFR1 FGFR2 KRAS TP53
8
Show member pathways
12.68 EGFR FGFR1 FGFR2 KRAS PIK3CA PRKCI
9
Show member pathways
12.66 EGFR FGFR1 FGFR2 KRAS PIK3CA TP53
10 12.61 EGFR FGFR1 FGFR2 KRAS PIK3CA
11 12.61 EGFR FGFR1 FGFR2 KRAS PIK3CA TP53
12
Show member pathways
12.52 EGFR KRAS PIK3CA PRKCI TP53
13 12.51 EGFR FGFR1 FGFR2 KRAS PIK3CA TP53
14
Show member pathways
12.4 FGFR1 FGFR2 KRAS PIK3CA PRKCI
15
Show member pathways
12.38 GPC3 KRAS PIK3CA PRKCI
16
Show member pathways
12.34 EGFR KRAS PIK3CA TP53
17
Show member pathways
12.29 EGFR KRAS PIK3CA TP53
18
Show member pathways
12.25 FGFR1 FGFR2 KRAS PIK3CA
19
Show member pathways
12.17 EGFR FGFR1 FGFR2 GPC3 KRAS PIK3CA
20
Show member pathways
12.16 EGFR FGFR1 FGFR2 KRAS PRKCI
21
Show member pathways
12.14 FGFR1 FGFR2 KRAS PIK3CA
22 12.07 ALK EGFR FGFR1 FGFR2
23
Show member pathways
12.07 EGFR FGFR1 FGFR2 KRAS TP53
24
Show member pathways
12.06 EGFR KRAS PIK3CA TP53
25 12.05 KEAP1 NFE2L2 PIK3CA TP53
26 12.04 EGFR FGFR1 GPC3 KRAS PIK3CA TP53
27 12.02 EGFR KRAS PIK3CA TP53
28 11.97 FGFR1 FGFR2 KRAS PIK3CA SOX2
29
Show member pathways
11.92 EGFR PRKCI TP53
30
Show member pathways
11.92 EGFR FGFR1 FGFR2 KRAS PIK3CA PRKCI
31
Show member pathways
11.84 EGFR KRAS PIK3CA
32
Show member pathways
11.83 FGFR1 KRAS PIK3CA
33 11.81 EGFR KRAS PIK3CA
34 11.79 KRAS NFE2L2 TP53
35
Show member pathways
11.74 FGFR1 KRAS PIK3CA PRKCI
36 11.72 EGFR KRAS TP53
37
Show member pathways
11.66 PIK3CA PRKCI TP53
38 11.53 EGFR NFE2L2 TP53
39 11.5 CYP1A1 EGFR NFE2L2
40 11.48 FGFR1 FGFR2 PIK3CA
41 11.39 CYP1A1 EGFR KRAS NFE2L2
42 11.28 EGFR KRAS PRKCI TP53
43 11.28 EGFR FGFR1 FGFR2 PRKCI
44 11.18 EGFR KRAS PIK3CA
45 10.91 EGFR FGFR1 FGFR2 KRAS PIK3CA TP53
46 10.83 KEAP1 NFE2L2 PIK3CA

GO Terms for Lung Squamous Cell Carcinoma

Biological processes related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 30)
id Name GO ID Score Top Affiliating Genes
1 cell proliferation GO:0008283 9.97 ALK CYP1A1 EGFR FAM83B TP53
2 angiogenesis GO:0001525 9.93 FGFR1 FGFR2 PIK3CA S100A7
3 regulation of gene expression GO:0010468 9.91 FGFR1 PIK3CA PTHLH SOX2
4 protein autophosphorylation GO:0046777 9.86 ALK EGFR FGFR1 FGFR2
5 peptidyl-tyrosine phosphorylation GO:0018108 9.85 ALK EGFR FGFR1 FGFR2
6 positive regulation of MAPK cascade GO:0043410 9.82 FGFR1 FGFR2 SOX2
7 cellular response to drug GO:0035690 9.79 EGFR NFE2L2 TP53
8 negative regulation of epithelial cell proliferation GO:0050680 9.76 FGFR2 GPC3 SOX2
9 positive regulation of MAP kinase activity GO:0043406 9.75 EGFR FGFR1 KRAS
10 phosphatidylinositol phosphorylation GO:0046854 9.71 EGFR FGFR1 FGFR2 PIK3CA
11 phosphatidylinositol-3-phosphate biosynthetic process GO:0036092 9.7 FGFR1 FGFR2 PIK3CA
12 ERBB2 signaling pathway GO:0038128 9.65 EGFR KRAS PIK3CA
13 branching involved in salivary gland morphogenesis GO:0060445 9.64 FGFR1 FGFR2
14 salivary gland morphogenesis GO:0007435 9.63 EGFR FGFR1
15 lung-associated mesenchyme development GO:0060484 9.62 FGFR1 FGFR2
16 mesenchymal cell differentiation GO:0048762 9.62 FGFR1 FGFR2
17 lung development GO:0030324 9.62 EGFR FGFR1 FGFR2 GPC3
18 positive regulation of glucose import GO:0046326 9.61 GPC3 NFE2L2 PRKCI
19 positive regulation of phospholipase activity GO:0010518 9.6 FGFR1 FGFR2
20 liver development GO:0001889 9.56 CYP1A1 EGFR KRAS PIK3CA
21 proteasomal ubiquitin-independent protein catabolic process GO:0010499 9.51 KEAP1 NFE2L2
22 orbitofrontal cortex development GO:0021769 9.49 FGFR1 FGFR2
23 ventricular zone neuroblast division GO:0021847 9.46 FGFR1 FGFR2
24 regulation of phosphatidylinositol 3-kinase signaling GO:0014066 9.46 EGFR FGFR1 FGFR2 PIK3CA
25 fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development GO:0035607 9.37 FGFR1 FGFR2
26 epidermal growth factor receptor signaling pathway GO:0007173 9.26 EGFR FAM83B KRAS PIK3CA
27 phosphatidylinositol-mediated signaling GO:0048015 9.02 EGFR FGFR1 FGFR2 PIK3CA TP53
28 phosphorylation GO:0016310 10.07 ALK EGFR FGFR1 FGFR2 PIK3CA PRKCI
29 positive regulation of cell proliferation GO:0008284 10.04 EGFR FGFR1 FGFR2 KRAS PTHLH
30 protein phosphorylation GO:0006468 10.01 ALK EGFR FGFR1 FGFR2 PIK3CA PRKCI

Molecular functions related to Lung Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.88 ALK EGFR FGFR1 FGFR2 PIK3CA PRKCI
2 protein kinase activity GO:0004672 9.83 ALK EGFR FGFR1 FGFR2 PRKCI
3 nucleotide binding GO:0000166 9.77 EGFR FGFR1 FGFR2 KRAS PRKCI
4 protein tyrosine kinase activity GO:0004713 9.62 ALK EGFR FGFR1 FGFR2
5 1-phosphatidylinositol-3-kinase activity GO:0016303 9.33 FGFR1 FGFR2 PIK3CA
6 fibroblast growth factor-activated receptor activity GO:0005007 9.26 FGFR1 FGFR2
7 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.26 EGFR FGFR1 FGFR2 PIK3CA
8 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.92 ALK EGFR FGFR1 FGFR2

Sources for Lung Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....